Atsaves, V., Leventaki, V., Rassidakis, G.Z. and Claret, F.X. (2019) AP-1 Transcription Factors as Regulators of Immune Responses in Cancer. Cancers, 11, Article No. 1037.
https://doi.org/10.3390/cancers11071037

has been cited by the following article:

• TITLE: Four-Year Maintenance Therapy with Cyclosporin A for Patients with Steroid-Refractory Idiopathic Minimal Change Disease Allergic to Rituximab

  AUTHORS: Kamel El-Reshaid, Shaikha Al-Bader, Hossameldin Tawfik Sallam, John Patrick Madda

  KEYWORDS: Corticosteroids, Cyclosporin A, Rituximab, Nephrotic Syndrome, Minimal Change Disease, Maintenance, Therapy

  JOURNAL NAME: Open Journal of Nephrology, Vol.14 No.4, November 27, 2024

  ABSTRACT: Background: Patients with Steroid-Refractory Idiopathic Minimal change disease (SRIM) have high morbidity and mortality and inherent side effects of immunosuppressive therapy. Except for its cost, R has been shown to be the most practical, safe and effective maintenance therapy for patients with multiple glomerulopathy, including those with SRIM. Being a monoclonal antibody, hypersensitivity reactions are common, and its use is limited in 10% of treated patients. Cyclosporin A (Cy) was a useful alternative, yet it had the potential for chronic interstitial fibrosis in the long term. Hence, a safe management protocol, for its use, was sought. Patients and methods: Over the past 10 years a total of 35 patients were treated with Cyc for SRIM, 11 of whom were children (